Ferroptosis-Related Genes with Regard to CTLA-4 and Immune Infiltration in Hepatocellular Carcinoma

被引：0
作者：
Jiahao Xu
Xing Wu
Xiaoyan Wang
机构：
[1] The Third Xiangya Hospital of Central South University,Department of Gastroenterology
来源：
Biochemical Genetics | 2023年 / 61卷
关键词：
Ferroptosis; Hepatocellular carcinoma; Immune infiltration; SLC7A11; CTLA-4;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Comprehensive analysis of ferroptosis in Hepatocellular Carcinoma (HCC) and its relation to the tumor immune microenvironment are needed. Data included HCC in The Cancer Genome Atlas and International Cancer Genome Consortium. And two datasets from Gene Expression Omnibus (GEO) were used as the validation set. Based on the expression of ferroptosis-related genes, HCC patients were divided into two subtypes. Cluster 1 showed lower tumor grade, lower CTLA-4, and a more favorable prognosis than Cluster 2. Patients with higher SLC7A11 (50%) had a poorer prognosis in HCC. SLC7A11 is characterized by more NK CD56bright cells, less DC, and neuroactive ligand–receptor interaction and cytokine receptor interaction. Ferroptosis-related genes especially SLC7A11 might be a valuable prognostic factor in HCC.
引用
收藏
页码：687 / 703
页数：16
相关论文
共 276 条
  • [1] Angeli JPF(2017)Ferroptosis inhibition: mechanisms and opportunities Trends Pharmacol Sci 38 489-498
  • [2] Shah R(2022)Ferroptosis: a new strategy for cancer therapy Front Oncol 12 830561-146
  • [3] Pratt DA(2014)Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy Nat Rev Cancer 14 135-1072
  • [4] Conrad M(2012)Ferroptosis: an iron-dependent form of nonapoptotic cell death Cell 149 1060-551
  • [5] Chen Y(2017)Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma J Hepatol 66 545-2502
  • [6] Fan Z(2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Lancet 389 2492-242
  • [7] Hu S(2010)The PD-1 pathway in tolerance and autoimmunity Immunol Rev 236 219-865
  • [8] Lu C(2021)YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis EMBO Mol Med 13 e14351-168
  • [9] Xiang Y(2016)Dendritic cells and cancer immunity Trends Immunol 37 855-1766
  • [10] Liao S(2017)Targets for immunotherapy of liver cancer J Hepatol 278 121137-1429
12345678910